Ajanta Pharma Limited (BOM: 532331)

India flag India · Delayed Price · Currency is INR
2,865.20
-50.30 (-1.73%)
At close: Dec 6, 2024
45.62%
Market Cap 357.78B
Revenue (ttm) 44.91B
Net Income (ttm) 8.75B
Shares Out n/a
EPS (ttm) 69.60
PE Ratio 40.89
Forward PE n/a
Dividend n/a
Ex-Dividend Date Nov 6, 2024
Volume 3,825
Open 2,915.55
Previous Close 2,915.50
Day's Range 2,842.30 - 2,945.00
52-Week Range 1,852.55 - 3,485.75
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Jan 27, 2025

About Ajanta Pharma

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited ... [Read more]

Industry Pharmaceutical Preparations
Founded 1973
Employees 8,073
Stock Exchange Bombay Stock Exchange
Ticker Symbol 532331
Full Company Profile

Financial Performance

In 2023, Ajanta Pharma's revenue was 42.09 billion, an increase of 12.45% compared to the previous year's 37.43 billion. Earnings were 8.16 billion, an increase of 38.81%.

Financial Statements

News

Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%

The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...

4 days ago - Business Upturn

Ajanta Pharma declares first interim dividend of ₹28 per share for FY25

Ajanta Pharma Ltd. has announced its first interim dividend for the financial year 2024-25. Each share with a face value of ₹2 will receive a dividend of ₹28, totaling an outlay of ₹350 crore. The com...

5 weeks ago - Business Upturn

Ajanta Pharma Q2 FY25 Results: Revenue rises 15% to ₹1,187 crore, net profit grows 11% to ₹216 crore

Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, has released its Q2 FY25 results, showcasing a strong performance for the quarter and half-year ending on 30th September 2024. Key H...

5 weeks ago - Business Upturn